Momentum Trades

MomentumOptionsTrading.com Weekly Wrap for 4/3/11

10:10pm (EST)

1.  Market Summary – First-Quarter Review

2.  Rare Element Resources (REE) – A Highly Volatile Play

3.  PharmAthene (PIP) – A Big Winner Bet              

4.  Earnings 

5.  Weekly Wrap Portfolio Update 

6.  Week Ahead

(To view the charts, please log into the Weekly Wrap Premium section)

= = = = = = = = = = = = = = =  

1. Market Summary – First-Quarter Review

No other country can substitute for the U.S.  The U.S. is still number one in military, number one in economy, number one in promoting human rights, and number one in idealism.  Only the U.S. can lead the world.  No other can. – Senior Korean official (to Thomas Friedman, NY Times Foreign Affairs columnist, February 2009)…

The bulls continued their comeback from the mid-March lows after having another solid week and pushing the market back towards its February and 52-week highs.  It all came down to Friday’s jobs report and it was a “winner”.  We aren’t sure if Charlie Sheen was impressed with Friday’s 8.8% unemployment rate and the 216,000 jobs added but we were.

The market ended the first quarter with a bang and got off to a nice start for 2Q after getting its best nonfarm payroll numbers in two years.

The Dow traded to an intraday 52-week high of 12,419 before finishing with a 57 point gain on Friday and settled at 12,376.  For the week, the index added 156 points, or 1.3%.  For the first-quarter (January-March), the blue chips advanced nearly 800 points, or 6.4%, which was the best quarterly gain since 1999. 

The S&P 500 added 6 points to finish at 1,332 and held the 1,300 level all week.  The index also made a strong move above 1,325 on Wednesday and reached a high of 1,337 on Friday.  For the week, the S&P jumped 19 points, or 1.4%; for the quarter the index popped 75 points, or 5.4%.

The Nasdaq cleared 2,800 on Friday but closed slightly below this level with a gain of 8 points, to 2,789.  Tech has led the recent charge off the mid-March lows and advanced 46 points, or 1.7%, for the week.  For the first 3 months of 2011, the Nasdaq was up nearly 140 points, or 4.8%.      

We mentioned on Thursday that if the unemployment rate came in below 8.9% we could see new highs.  The 5-week “trading range” the market has been in since mid-February is on the verge of a breakout and here were our thoughts in late January before the range:

“The Dow gained 4 points to close at 11,989 but made its second straight trip above 12,000, hitting 12,019 intraday.  We mentioned yesterday the index has a shot at 12,300-12,350 over the near-term and we would like to see a close above 12K today.

The S&P 500 finally kissed 1,300, twice, once in the morning and once in the afternoon before finishing just below resistance at 1,299.54 – up 3 points.  We are looking for a pop to 1,325 and maybe 1,350 on a breakout. 

The Nasdaq was the strong horse as it added 15 points, or 0.6%, to settle at 2,755.  The index is still 9% away from our 3,000 target and we have said it may be hard to reach this level over the near-term.  We may only get to 2,850.” (END)

On February 17, after a trip to these levels, we had this to say:

“The only number we have been watching this week is 1,334 which represented a double or a 100% rise from the S&P 500’s low of 667 back in 2009.  We said last Friday that “1,325 Changes Everything” and only confirmed our target of 1,350 was in the cards.  The index battled 1,334 for 3 sessions before breaking through yesterday after gaining 8 points to close at 1,336.  Back in mid-January we said if the bulls could get past 1,300 then we could see 1,450-1,500 in 2011.  However, let’s get to 1,350 first. 

The Dow actually traded into our target zone of 12,300-12,350 after kissing 12,303 but finished the day at 12,288, up 61 points.  If the upper-end of our zone is taken out then the bulls will be gunning for 12,500-12,600 over the near-term with a run to 13,000 coming if the momentum can last until April.

As for the Nasdaq, the index finished at 2,825, up 21 points, and closed right in the middle of our 2,800-2,850 targets.  Of course, we have been mentioning a run to 3,000 since the beginning of the year and a break above here gets the bulls there.” (END)

The market appears to be moving past the Libya and Middle East crisis although oil continues to move higher.  Japan seems to be hitting the ground running as rebuilding efforts have already begun.  And America’s economy seems to be getting better despite the fact that housing remains in the doldrums.

The CBOE Market Volatility Index (^VIX, 17.40, down 0.34) traded down to 16.44 on Friday after touching 31.28 in mid-March.  We mentioned last week the index could fall to 14-13 on another leg up which is when we think the bulls might take a break.

A VIX reading under 20 indicates confidence and calm while a reading above 30 indicates nervousness and panic. 

We also mentioned the iPath S&P 500 VIX (VXX, $29.09, down $0.28) could head lower if the market rallied higher.  The April 30 puts (VXX110416P00030000, $1.85, up $0.09) were at $1.50 last Sunday and gained over 20% by the end of the week.

We are hoping for one big charge by the bulls over the next few weeks and we would like to see a strong start to this week to get us there.  April is normally the Dow’s best month and has posted gains of 2%, on average, for the past 60 years.  Of course, history doesn’t always repeat itself but the catalyst for the market breaking out to new highs will be first quarter earnings which begin next Monday.

Alcoa (AA, $17.47, down $0.19) will announce their results on 4/11.  Keep an eye on our aforementioned near-term targets for this week: Dow 12,500-600; S&P 500 1,350; and Nasdaq 2,850.  If these levels are cleared then we could go into earnings season looking to test our upper-end 2011 targets for the indexes.

= = = = = = = = = = = = = = = 

2.  Rare Element Resources (REE) – A Highly Volatile Play

After having quadrupled in value in the last 52-weeks on news that China would cut rare earth export quotas, is Rare Element Resources (REE, $13.02, down $0.15) still a good value?  The technical picture is giving mixed signals, but fundamentals are strong.

Rare earths are actually not that rare.  Cerium is the 25th most abundant element in the earth’s crust.  While more abundant than many other earth minerals, they are not concentrated enough to make them easily exploitable economically.  The table below lists the 17 rare earths and some of their uses.

Sc

Scandium

Aircraft parts

Y

Yttrium

Lasers, High-temperature superconductor

La

Lanthium

Battery electrodes, Camera lens

Ce

Cerium

Oxidizing agent, Catalyst for oil refineries

Pr

Praseodymium

Magnets, Lasers

Nd

Neodymium

Magnets, Lasers, Violet colors in ceramics

Pm

Promethium

Nuclear batteries

Sm

Samarium

Magnets, Lasers, Neutron capture

Eu

Europium

Lasers, Mercury-vapor lamp

Gd

Gadolinium

Magnets, Lasers, X-ray tubes, Computer memories

Tb

Terbium

Lasers, Fluorescent lamps

Dy

Dysprosium

Magnets, Lasers

Ho

Holmium

Lasers

Er

Erbium

Lasers, Vanadium steel

Tm

Thulium

Portable X-ray machines

Yb

Ytterbium

Infrared lasers, Chemical reducing agents

Lu

Lutetium

PET scan detectors

As one can see, many of the rare earths are used in high-performance magnets and lasers.  They are also a key component in military lasers, radar, missiles, guided bombs, aircraft electronics, night-vision goggles, and defense systems.  Additionally, rare earths are used in TV displays, cell phones, hybrid electric motors, and wind turbines.  Computer hard drives use magnets made from rare earths.  Each wind turbine requires a huge magnet, consuming about a ton of rare earths.  And rare earths are crucial to hybrid cars.  As the United States moves to more green power such as wind, rare earths will become more and more in demand.

The recent earthquake in Japan may help rare earth demand more than it hurts it.  The nuclear spill may cause more nations to favor green energy over nuclear energy.  The opposite side is that Japan is the largest importer of rare earths in the world, consuming almost 50% of the total output.

China has about 30% of world’s deposits but, mainly due to lax environmental standards, currently produces more than 96% of the global supply.  However, as China tightens its environmental controls and its robust economy continues to consume rare earths, it is predicted that by 2015 the country will become a net importer, thus further pressuring prices. 

The country has been hiking export quotas, limiting world supply.  And as of April 1, China imposed a heavier tax on the minerals.  According to the Chinese state-owned media, Xinhau, the tax has been set at 60 yuan ($9.14) per ton of light rare earth minerals, and 30 yuan ($4.57) per ton of medium and heavy rare earth minerals.  Light rare earths are La-Sm, and heavy rare earths are Eu-Lu.

Reuters reported last week that the Chinese raised the price for rare earth metals past the $100,000-per-ton mark — the first time ever that the price per ton has vaulted into the six-figure range.  According to the report, that’s an almost nine-fold increase from a year ago, and recent prices are up an astonishing $34,000 per ton in the last month alone. 

This is a lot, especially if Canada’s Rare Element Resources has the 17.5 million tons of rare earths it claims.  The company owns 100% of the Bear Lodge deposit in Wyoming, which holds mainly light rare earth elements.  Many U.S. deposits lack the heavy rare earth elements critical for much of today’s technological innovations, but regardless of the type of rare earth, it is crucial for the country’s security to develop a strategic stockpile.  China has been doing the same.  Recycling of rare earths is costly and only yields small quantities.  At current prices, it is uneconomical, but will become more in favor as prices go higher.

Rare Element Resources, along with California-based Molycorp (MCP, $59.25, down $0.77), are one way the government can achieve such a strategic stockpile.  Based on the high ore grades from REE’s drill holes, the company expects to be able to produce rare earths at low costs when it starts mining in 2015.  However, Molycorp’s mines are expected to become operational in 2012, beating REE by three years.  So no doubt, there will be competition.

But there is a bonus package with Rare Element Resources as it produces more than just rare earths.  It also produces a small amount of gold.  From a recent study, they estimated that the Sundance gold project has 947,000 ounces of gold.  At gold’s current price of over $1,400 an ounce, that is a total reserve of over $1.3 billion, far higher than the company’s current market cap of $562 million.  And this is just one mine.

From the charts below, three out of the four indicators (MFI, stochastic %K and %D, and the W%R) are in or nearing overbought signals, a bearish sign.  However, the vertical purple line shows the last time when all the technical’s were at similar levels, as circled in purple, the stock started an upward climb.  The orange line represents the decline after a breakout.  However, only the stochastic %K and %D and the W%R were at the same level as they are now.  Both the MFI and RSI were above their current levels, as circled in orange.

The current stock price seems to be stuck in the $12-$13 trading range.  Support is at $9.50, and long-term resistance is at $18.  Shares have bounced off support since mid-March on strong call option volume and are at near-term resistance ($14-$15).


On March 22, there was heavy volume in the REE April 12.50 calls (REE110416C00012500, $1.05, down $0.05) which easily doubled as traders took advantage of a 25% jump from $10.38 to $12.88, the day before.

Will the stock go higher from here?  From the above analysis, it could reach $18, which is the resistance line as shown in the chart.  But how long will it take to get there?  It could zoom up very fast, seeing that it zoomed from $10 to $18 in early January in 15 days.  But to take a conservative rate of increase, we will use a rise of $0.13 a day.  Starting from a current price of $13.02, it will take 38 days to reach $18.

Based on Friday’s market activity, the April 14 calls (REE110416C00014000, $0.40, down $0.05) were the most popular and could be worth a gamble.  However, the May 15 calls (REE110521C00015000, $0.60, down $0.10) might be the better play for those of you wanting to speculate.

The Rare Earth ETF (REMX, $26.61, up $0.31) is another way to play a higher move in the sector.  Although volume is light, the May 28 calls (REMX110521C00028000, $0.85, up $0.05) might also be worth a look.

= = = = = = = = = = = = = = = 

3.  PharmAthene (PIP) – A Big Winner Bet

PharmAthene (PIP, $3.11, down $0.08) has two things going for it.  First, it is pending an ongoing court battle with Siga Technologies (SIGA, $12.80, up $0.70) on marketing rights for a drug to treat smallpox.  The government gave SIGA $2.8 billion, and the company may be entitled to a portion of that.  Second, PharmAthene has been collaborating with the government on a new anthrax drug, which if successful, could also provide significant revenue.  We are also seeing some insider buying which is usually positive news.

On the lawsuit against SIGA, PharmAthene will very likely win.  Basically, the two companies were prepared to merge back in 2006.  It was agreed that if the merger did not go through, PharmAthene would receive licensing rights for SIGA’s smallpox vaccine.  Well, the merger broke up and they have not received anything from SIGA.  In 2009, the government placed an order for SIGA’s smallpox vaccine, potentially worth $2.8 billion.  Thus, if PharmAthene prevails in its lawsuit, the company is entitled to a share of the profits.  Giving the company’s market cap of about $127 million, shares could easily double with a win.  A judge’s decision is due out in July, or possibly sooner.

For national security, the government is required to have a sufficient stockpile of anthrax vaccine.  Current anthrax drugs have shown problems with swelling and the company’s next generation version requires fewer doses and costs nearly three times less.  The government is spending $80 million while working with PharmAthene which recently released positive data of studies on their anthrax drug, Valortim.

From May to January, insiders have been buying large amounts of shares.  Insiders buy shares for two reasons: to save the company or because shares are undervalued.  We feel in this case, it is the latter.  Insider buys and sells can be very useful when determining if a drug company has promise down the road and we think there is something here.

Although technicals can have little effect on a Biotech stock movement right before news on a drug, it is interesting to notice that three out of the four technicals (RSI, stochastic %K and %D, and W%R) are at or near oversold territories, a bullish signal.  But even more bullish is that the times when the stock price rose were at points where the technicals were at the same levels, as shown by a purple line and circle.

Plus, the price seems to be approaching the support line, so there is little downside, except if really bad news regarding the lawsuit or their anthrax drug occurs.


We believe these events could push shares past $6 and up to $10 or the stock will fall below $2.  The stock is a “safer” way to play these events but what about the options? 

To ensure the benefit of the judge’s decision, which will sway the stock either up or down, you could buy the September 5 calls (PIP110917C00005000, $0.40, flat), since we bet the judge will rule in PharmAthene’s favor.  If the stock reached $6, the trade would be a double.  However, if shares hit $10 the options would be worth at least $5, or 10 times more than their current value.

The June 5 calls (PIP110618C00005000, $0.25, flat) could also do well but they are a lot more risky.

To be safe, you could purchase both the September 5 calls and the September 2.50 puts (PIP110917P00002500, $0.45, flat) puts.  The stock would need to fall below $2 or trade above $6 which would be your breakeven points.

The bottom line is that the September 5 calls are “cheap” options to speculate with on an investment that could make you 10x your investment.  We aren’t ready to jump on them yet, but we will be following them for clues on a possible earlier verdict.  

= = = = = = = = = = = = = = = 

4.  Earnings

The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter.  If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week.  The first set of companies report before the bell that day, the second set after the market closes.  (Quotes are as of Friday’s close, 4/1/11).

MONDAY

Dreams (DRJ, $2.29 down $0.03), Schnitzer Steel Industries (SCHN, $65.83, up $0.82)

Schnitzer Steel could report good earnings and we will be watching the April 70 calls (SCHN110416C00070000, $0.55, flat) on Monday for a possible trade for our Daily publication.  However, shares would need to move 7%-8% to get these call in-the-money so we will probably sit on the sidelines.

TUESDAY

Electro Rent (ELRC, $17.32, up $0.14), Zep (ZEP, $17.39, down $0.02), Hooker Furniture (HOFT, $11.85, down $0.11), KB Home (KBH, $12.43, down $0.01), Mitcham Industries (MIND, $13.76, up $0.11), Team (TISI, $25.90, down $0.36)

WEDNESDAY

Monsanto (MON, $73.17, up $0.91), Apogee Enterprises (APOG, $13.32, up $0.13), Bed Bath & Beyond (BBBY, $48.71, up $0.44), Pep Boys-Manny Moe & Jack (PBY, $12.75, up $0.04), Ruby Tuesday (RT, $13.19, up $0.08), WD-40 Co. (WDFC, $42.72, up $0.38)

We like Monsanto and may look at adding some call options to our Watch List to play a possible move higher.

THURSDAY

Constellation Brands (STZ, $20.50, up $0.22), International Speedway (ISCA, $30.37, up $0.57), MSC Industrial Direct (MSM, $69.48, up $1.01), MSCI (MSCI, $38.18 up $1.36), Pier 1 Imports (PIR, $10.27, up $0.12), Rite Aid (RAD, $1.05, down $0.01), Bassett Furniture Industries 1 (BSET, $7.79 down $0.02)

We tried playing STZ last time out and their beers sales came in below expectations.  If there is an improvement, the stock could jump 5% on good results.

FRIDAY

Blyth (BTH, $32.85, up $0.36)

= = = = = = = = = = = = = = = 

5.  Weekly Wrap Covered Call Portfolio Update (Closing prices as of 4/1/11)

Cisco Systems (CSCO, $17.04, down $0.11)

May 18 call (CSCO110521C00018000, $0.35, down $0.05)

Entry Price:  $17.14 (3/17/11) sold May 18 calls @ $0.56

Exit Target: $20+

Return: 3%

Stop Target: None

Action:  Shares could stay in a trading range like they did in 2009 (green box) of $15-$17 for a few months which is all we are looking for before a test back to $20 in 6-12 months.


We recommended buying the stock at $17.14 on 3/17/11 and for every 100 shares to sell the May 18 call for 56 cents.  This lowered the cost basis to $16.58. 

If shares are called away by mid-May at $18 the trades makes 9%.

  

TiVo (TIVO, $9.16, up $0.41)

April 10 calls (TIVO110416C00009000, $0.67, up $0.16)

Entry Price:  $8.80 (3/14/11) sold April 10 calls @ $1.00

Exit Target: $10+

Return: 16%

Stop Target: None

Action:  The April options expire in 12 days.  Shares surged nearly 5% on Friday and there is a real good chance we get “called away”.  If so, the trade will return 27%.  If the stock stays under $10, we will look to sell another call option.


Shares opened at $8.79 on 3/14/11 and the calls could have been sold for $1.00.  This lowered the cost basis to $7.80.  TiVo is a very risky stock to own due to litigation issues but the options have some nice premiums.   

 

Spreadtrum Communications (SPRD, $18.23, down $0.32)   

Entry Price:  $23.45 (2/7/11) sold March 24 calls @ $0.95

Exit Target: $30

Return: -19%

Stop Target: None

Action:  After trading near $20 for much of last week, it appears shares could be setting up for a trading range.  Our 6-12 month price target for the stock is $30 but we will need a close above $20 to sell another call option.


Shares opened at $23.43 on 2/7/11 and the calls could have been sold for 95 cents.  This lowered the cost basis to $22.48.   


DryShips (DRYS, $4.78, down $0.17)

January 2012 7.50 call (DRYS120121C00007500, $0.26, down $0.04)   

Entry Price:  $5.25 (1/03/11) sold January 2012 7.50 call @ $0.65

Exit Target: $8

Return: 4%

Stop Target: None

Action:  DryShips announces earnings and moved past $5 last week before slipping over 3% on Friday.  We are still looking for a trip up into the $5-$6 trading range (between red and black lines).


DryShips opened at $5.37 on 1/3/11 and shares were at $5.25 shortly after the bell.  The options could have been sold for 65 cents which lowered the cost basis to $4.60.

If shares are over $7.50 by January 2012, the stock will be “called away” and the trade would make nearly 65% for those who joined us at the beginning of the year.  We like the risk/reward factor these options offer.

 

Seattle Genetics (SGEN, $15.50, down $0.07)


NEW TRADE!!!


Sell the June 17.50 calls (SGEN110618C00017500, $0.75, flat) on Monday


Entry Price:  $15.50 (12/27/10) sold March 17.50 calls @ $0.90

Exit Target: $20

Return: 6%

Stop Target: None

Action:  We said last week shares looked poised to break $15 and they did.  The June 17.50 call options are going for 75 cents and this level will serve as strong resistance.  If we sell them on Monday (4/4/11) it would lower the cost basis to $13.85.  If shares are called away by mid-June at $17.50 the trade returns 26%.

Seattle Genetics plans to file an application with the FDA seeking approval for its SGN-35 drug which treats Hodgkin’s disease.  The company believes the drug has the potential to be the standard of care with chemotherapy for 100% of newly diagnosed Hodgkin’s patients.


Seattle Genetics opened at $15.80 and shares were at $15.50 at 10am on 2/27/10.  The March 17.50 call option could have been sold for 90 cents.  This lowered the cost basis to $14.60.  We like this company a lot going forward and their pipeline.   


Dendreon (DNDN, $37.41, down $0.02)     

Entry Price:  $41.96 (9/13/10) sold October 45 call @ $1.30, (11/11/10) sold December call @$1.75, (12/20/10) sold February 39 call @ $1.50

Exit Target: $45

Return: 0%

Stop Target: None

Action:  Shares surge $4 last week and touched a high of $37.75 on Friday.  The break out of its trading range (black and red lines) was strong but you can see the next layer of resistance is pretty heavy as well (green line).  Dendreon recently got the go ahead from the FDA to increase production of Provenge, its prostate cancer fighting drug and it appears the costs will be covered.  We want to wait until shares trade above $40 before writing another call.


Dendreon opened at $41.96 and you could have sold the October 45 call option for $1.30 on 9/13/10.  This lowered the cost basis to $40.66.

On 11/11/10 we sold the December 40 call option for $1.75 which lowered our cost basis to $38.91.

On 12/20/10 we sold the February 39 call option for $1.50 which lowered our cost basis to $37.41.

= = = = = = = = = = = = = = =  

6.  Week Ahead

Next week is the start of 1Q earnings and the economic calendar is light.  This could be a good thing but we expect volume to remain below average as traders get ready for earnings season. 

On Monday, Federal Reserve Chairman Ben Bernanke will deliver a speech at the Atlanta Fed conference and will likely comment about the jobs report.  Hopefully, he appears calm and relaxed.  We will be watching his body language if there is a Q&A session.

For Tuesday, Wall Street will get the latest numbers from the Institute for Supply Management’s (ISM) non-manufacturing index for March.  Additionally, the minutes from the latest meeting from the Federal Open Market Committee (FOMC) are scheduled to be released.

The Chicago Fed’s manufacturing index for February is due out on Wednesday along with oil inventories. 


On Thursday, we get another look at the weekly jobless claims and February’s consumer credit report.  Friday the market will get briefed on wholesale inventories for February.

]]>

Scroll to Top